Last reviewed · How we verify
Fp MDPI
Fp MDPI is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune cell trafficking.
Fp MDPI is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune cell trafficking. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | Fp MDPI |
|---|---|
| Also known as | - fluticasone propionate multidose dry powder inhaler, fluticasone propionate, inhaled corticosteroid, Fp SPIROMAX® Inhalation Powder, Fp Spiromax |
| Sponsor | Teva Branded Pharmaceutical Products R&D, Inc. |
| Drug class | S1P receptor modulator |
| Target | S1PR1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to S1PR1, Fp MDPI inhibits the egress of lymphocytes from lymphoid organs, thereby reducing inflammation and autoimmune responses. This mechanism is thought to be beneficial in the treatment of autoimmune diseases such as multiple sclerosis.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old (PHASE1)
- Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma (PHASE3)
- Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older (PHASE1)
- Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (PHASE3)
- Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma (PHASE3)
- A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma (PHASE1)
- A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |